Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion
- 30 October 2005
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature
- Vol. 438 (7064), 99-102
- https://doi.org/10.1038/nature04055
Abstract
Human immunodeficiency virus type 1 (HIV-1) continues to spread, principally by heterosexual sex, but no vaccine is available1. Hence, alternative prevention methods are needed to supplement educational and behavioural-modification programmes. One such approach is a vaginal microbicide: the application of inhibitory compounds before intercourse2. Here, we have evaluated the microbicide concept using the rhesus macaque ‘high dose’ vaginal transmission model with a CCR5-receptor-using simian–human immunodeficiency virus (SHIV-162P3) and three compounds that inhibit different stages of the virus–cell attachment and entry process. These compounds are BMS-378806, a small molecule that binds the viral gp120 glycoprotein and prevents its attachment to the CD4 and CCR5 receptors3,4, CMPD167, a small molecule that binds to CCR5 to inhibit gp120 association5, and C52L, a bacterially expressed peptide inhibitor of gp41-mediated fusion6. In vitro, all three compounds inhibit infection of T cells and cervical tissue explants, and C52L acts synergistically with CMPD167 or BMS-378806 to inhibit infection of cell lines. In vivo, significant protection was achieved using each compound alone and in combinations. CMPD167 and BMS-378806 were protective even when applied 6 h before challenge.This publication has 27 references indexed in Scilit:
- Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency VirusJournal of Virology, 2005
- Multiple Vaginal Exposures to Low Doses of R5 Simian‐Human Immunodeficiency Virus: Strategy to Study HIV Preclinical Interventions in Nonhuman PrimatesThe Journal of Infectious Diseases, 2005
- The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry InhibitorMolecular Pharmacology, 2005
- Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical TissueThe Journal of Experimental Medicine, 2004
- Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytesNature Reviews Drug Discovery, 2004
- Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compoundsBioorganic & Medicinal Chemistry Letters, 2004
- Cyanovirin-N Inhibits AIDS Virus Infections in Vaginal Transmission ModelsAIDS Research and Human Retroviruses, 2004
- Inhibiting sexual transmission of HIV-1 infectionNature Reviews Microbiology, 2003
- Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 InteractionsJournal of Virology, 2003
- Enhanced: The Need for a Global HIV Vaccine EnterpriseScience, 2003